| Name | Title | Contact Details |
|---|---|---|
Rob Bickford |
Senior Director, Finance | Profile |
Sean Smith |
Vice President, Finance | Profile |
Samantha Willing |
Vice President of People | Profile |
Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
Access BIO is a Boyce, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a team of inspired individuals, driven by love of science, commitment to collaboration, and relentless pursuit of excellence. Lumen`s technology allows it to create clever new high-value products in spirulina (Arthrospira platens), a type of blue-green algae.